In Vivo Preclinical Articles & Analysis
16 news found
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s ...
LB-100 has demonstrated synergistic action in in vivo preclinical mesenchymal tumors. GEIS will lead a European initiative to conduct a Phase 1/randomized II trial exploring the combination of doxorubicin plus LB-100 in first line of advanced soft tissue ...
First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease with liver transplantation or dietary restriction as the only treatments currently available ASC Therapeutics in partnership with the UMass Chan Medical School and the Clinic for Special Children (CSC), presented safety and efficacy results of a dual-function gene ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
In both therapeutic areas, Avidea’s product candidates have been validated in rigorous preclinical (in vivo) proof of concept studies and are within approximately 12 months of IND filing. ...
CorWave also made major progress in R&D, completing an unprecedented in vivo preclinical study2 in which its heart pump successfully operated in pulsatile mode, synchronizing with the native heart without the aid of sensors, for 90 days. ...
ByCorWave
Your main preoccupation is optimizing your preclinical and discovery studies? Find out how to use Inovotion’s cutting-edge in vivo technology in your future projects, presented by our experts. #1 How to optimize in vivo preclinical evaluation of synergistic immuni-oncology drug candidate. ...
“The Live Bacterial Therapeutic, MB097, arising from this signature, aims to tap into this predictive signature of ICI therapy response. Preclinical in vivo data and mechanistic in vitro human cell data generated thus far have been hugely encouraging. ...
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, clinically ...
Thanks to its team and the entire ecosystem around us, Puzzle has achieved major milestones in the past year: successful completion of multiple preclinical in-vivo implantations approval by U.S. FDA for Breakthrough Device Designation confirmation by USPTO of novelty and priority of 100% claims cited in our patents completion of a Clinical & Business ...
The whole pipeline covers oncolytic virus engineering, construction, in vitro validation study, in vivo preclinical study, disease-specific oncolytic virotherapy development, and oncolytic virotherapy development for combination therapy with cancer immunotherapy. ...
Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive positioning, and strengthen its business development and fundraising efforts. ...
ByAbologix
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. ...
The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane LVAD”, given by Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, is available on the 2020 ASAIO Virtual On-Demand Conference. ...
ByCorWave
MUNICH, Germany – October 2nd, 2019: After completing a 60-day pre-clinical study, Professor Stephen Wildhirt, MD, PhD, CEO at AdjuCor, is excited to report on its success. Apart from other achievements, the study confirmed the chronic physiologic acceptance of their non-blood-contacting biventricular cardiac support device by the body. AdjuCor has previously completed a successful 30-day ...
MicroVaccines SA (from now on “MV”) has been officially incorporated in Canton Ticino on October 26th, 2018 as a spin-off of the Institute for Research in Biomedicine (from now on “IRB”) by Dr. Fabio Grassi, M.D., Ph.D. “This is an incredible achievement for a researcher and M.D., whose ambition is to translate experimental findings to medical application” ...